非白人参与者入组情况及种族与族裔报告情况:针对多发性硬化疾病修正疗法的III期试验的系统综述
该系统综述检索了PubMed数据库1995年至2020年6月的数据,纳入44篇III期试验出版物(代表45项试验),评估已获批多发性硬化疾病修正疗法(DMT)III期试验中非白人群体代表性随时间的变化,以及医学期刊和制造商网站上种族与族裔的报告情况。结果显示,17篇(37.8%)未报告种族或族裔,14篇(31.1%)仅报告白人参与者比例,14篇(31.1%)报告了2个或以上种族/族裔;与多国人口普查数据相比,非白人多发性硬化患者在试验中显著代表性不足;所有面向患者或医疗保健提供者的DMT网站均未报告关键试验中的种族和族裔数据。
要点
- 44篇III期试验出版物中,37.8%未报告种族或族裔,31.1%仅报告白人比例,31.1%报告2个或以上种族/族裔。
- 与多国人口普查数据相比,非白人多发性硬化患者在试验中显著代表性不足。
- 所有面向患者或医疗保健提供者的DMT网站均未报告关键试验中的种族和族裔数据。
核心结论
- 多发性硬化DMT试验出版物中种族和族裔报告不足,制造商网站省略了种族和族裔代表性信息。
- 现有数据显示非白人多发性硬化患者在试验中显著代表性不足。
- 作者认为该信息的可及性对患者及其医疗保健提供者做出知情照护决策至关重要。
研究设计与样本
- 系统综述,检索PubMed数据库1995年至2020年6月,纳入制造商赞助的FDA批准多发性硬化DMT的III期试验。
- 共审查44篇III期试验出版物,代表45项试验。
- 分析非白人患者代表性随时间的变化,并与多国人口普查数据比较。
- 审查面向患者和医疗保健提供者的DMT网站,评估种族和族裔代表性信息的传播情况。
主要发现
- 44篇出版物中,17篇(37.8%)未报告种族或族裔,14篇(31.1%)仅报告白人参与者比例,14篇(31.1%)报告2个或以上种族/族裔。
- 与多国人口普查数据相比,非白人多发性硬化患者在试验中显著代表性不足。
- 由于缺乏数据,无法评估其他种族和族裔的代表性趋势。
- 所有面向患者或医疗保健提供者的DMT网站均未报告关键试验中的种族和族裔数据。
关键数值与推荐
- 44篇III期试验出版物中,17篇(37.8%)未报告种族或族裔,14篇(31.1%)仅报告白人参与者比例,14篇(31.1%)报告2个或以上种族/族裔。
- 与多国人口普查数据相比,非白人多发性硬化患者在试验中显著代表性不足。
临床怎么用
- 原文未据此给出推荐。
局限性
- 由于缺乏数据,无法评估其他种族和族裔的代表性趋势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Black and Hispanic people with multiple sclerosis (MS) (pMS) have been found to have different disease courses or worse outcomes associated with MS compared to White pMS. They are also more likely to be negatively affected by social determinants of health, further worsening disparities in outcomes. As these disparities may affect treatment response, non-White pMS must be included in trials for greater generalizability of research and therefore more inclusive treatment plans. In this study, we aimed to evaluate how representation of non-White groups in phase III trials of approved disease-modifying therapies (DMTs) has evolved over time and how race and ethnicity are reported in medical journals and on manufacturer websites. METHODS: We conducted a systematic review of the PubMed database from 1995 to June 2020 to identify manufacturer-sponsored phase III trials for Food and Drug Administration-approved MS DMTs. We explored how race and ethnicity were reported in trial publications. Using studies where information was available, we analyzed the representation of non-White pMS over time and compared to multinational census data. We reviewed patient- and health care provider (HCP)-facing websites of available DMTs to assess the dissemination of information on racial and ethnic representation in trials. RESULTS: A total of 44 phase III trial publications were reviewed, representing 45 trials, among which 17 (37.8%) did not report race or ethnicity, 14 (31.1%) reported race and ethnicity as proportion of White participants only, and 14 (31.1%) reported 2 or more races/ethnicities. When compared to multinational census data, non-White pMS were significantly underrepresented in MS trials. Due to lack of data, trends in representation of other races and ethnicities could not be assessed. No patient- or HCP-facing DMT websites reported data on race and ethnicity in pivotal trials. Study results are available on our study dashboard. CONCLUSION: Race and ethnicity are underreported in MS DMT trial publications and race and ethnic representation are omitted from manufacturer websites. When available, data show that non-White pMS are significantly underrepresented in MS trials. The availability of this information is crucial for patients, together with their HCPs, to make informed decisions about their care.
引用
- Onuorah HM, Charron O, Meltzer E, et al. Enrollment of Non-White Participants and Reporting of Race and Ethnicity in Phase III Trials of Multiple Sclerosis DMTs: A Systematic Review. Neurology. 2022. PMID: 35046135. doi:10.1212/WNL.0000000000013230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。